

MOUNTAIN VIEW, California, April 20, 2018 – Specific Diagnostics unveils the Reveal AST/ID™ system at the ECCMID Conference.

The Reveal AST/ID™ system provides phenotypic susceptibility and ID direct from positive blood cultures with traditional microdilution reliability, in hours not days.

Specific Diagnostics, which has developed innovative paradigms for detection, identification (ID) and antibiotic susceptibility testing (AST) of microorganisms announces that at ECCMID today the Company will showcase the Reveal AST/ID™ system which delivers phenotypic AST and ID in an average of 4 hours, directly from positive blood culture. The Reveal AST/ID system provides minimum inhibitory concentration (MIC) results with accuracies exceeding those of some reference methods, wide antimicrobial coverage, and identification of species responsible for bloodstream infections. With sample preparation just a simple dilution of a positive blood culture fluid, the Reveal system uniquely speeds time to answer while offering a cost enabling widespread adoption.

Specific's novel, patented small molecule sensor (SMS) arrays responds to the small, volatile, metabolic byproducts produced by microorganisms to detect growth, assess antibiotic efficacy, and determine microorganism ID. The Reveal AST assay is based on a standard 96-well microplate covered, after inoculation, with a sheet of SMS arrays, one SMS array™ positioned over each well, the responses of which very sensitively monitor metabolic emissions from the wells. Sample preparation is easy, only a simple dilution of a positive blood culture fluid.

Bloodstream infection leading to sepsis is responsible for more than half of all deaths in hospitals and is the most expensive condition treated in hospitals. Mortality rate increases 6% every hour from onset. Therefore, it is critical the right antibiotic treatment is determined quickly. Current methodologies require 2 days to determine the effective antibiotic while Specific's Reveal AST/ID provides antibiotic susceptibility results in hours. The Reveal AST/ID instrument and assay are cost effective and labor saving allowing clinics to readily deploy the Specific solution.

"We are looking forward to introducing the transformative Reveal AST/ID instrument and consumable assays at ECCMID, and making it available for clinical evaluation in 2018," said Ray Martino, Specific COO.

Specific and its founders have written almost 60 peer-reviewed publications, detailing the successful demonstration of the SMS array technology. The Company itself has independently authored over 20 scientific publications and conference abstracts detailing the SMS array powered detection, identification and antibiotic susceptibility testing.

About Specific

Specific Diagnostics has developed *in vitro* diagnostic systems for the detection and identification and determination of antibiotic susceptibility of microorganisms. The company's unique patented technology leverages a low-cost small molecule sensor array, enabling diagnostic products that simplify workflow and speed time-to-answer at low cost. Specific's system streamlines lab workflow, reduce costs, and substantially shorten the time from sample arrival to selection of effective therapy, saving patients faced with fast-moving and deadly drug-

Press Release – For Distribution

resistant blood infections. Specific is located in Mountain View, California. For more information, visit www.specificdx.com.

Corporate Contact:

Email: press@specificdx.com